$0.970
+0.013 (+1.37%)收盘时
FBLG 盈利能力与利润率
Evaluating the bottom line, Fibrobiologics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -660.08%, provide a clear picture of how effectively FBLG converts its operational activities into shareholder value.
FBLG 同业对比
In the context of the broader market, FBLG competes directly with industry leaders such as ENSC and XCUR. With a market capitalization of $6.78M, it holds a significant position in the sector. When comparing efficiency, FBLG's gross margin of N/A stands against ENSC's 100.00% and XCUR's N/A. Such benchmarking helps identify whether Fibrobiologics Inc is trading at a premium or discount relative to its financial performance.
Fibrobiologics Inc 财务表现
Fibrobiologics has been facing significant financial challenges, with a net income loss of -5,000,000 USD in Q1 2026 and a gross profit of 0 USD in Q4 2024. The company has a high debt-to-equity ratio of 335.21% in Q4 2024, indicating financial leverage that could pose risks.
Financials
相关文章
- Treasury Yields and the Stock Market: What a Near-5% 10-Year Yield Means for Investors in 2026The 10-year Treasury yield hit 5.31% in October 2026 before easing to 4.88%. Learn how Treasury yields affect stocks, which sectors react and how to plan.
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。